Vera Therapeutics Announces Acquisition of Monoclonal Antibody (MAU868) from Pfizer to Treat BK Virus (BKV) in Transplant Patients; BKV Is a Leading Cause of Transplant Loss and Transplant-Associated Morbidity; MAU868 Is Currently in Ongoing Phase 2 Clinical Trial, Possible First Effective Treatment for BKV

On December 17, 2021, Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients’ lives, announced that it has acquired MAU868, a first-in-class monoclonal antibody to treat BK virus (BKV) infections, and has entered into a credit facility with Oxford Finance LLC (Oxford) to provide borrowing capacity up to $50 million. MAU868, acquired from Amplyx Pharmaceuticals, Inc., a wholly owned subsidiary of Pfizer Inc., has the potential to neutralize infection by blocking BKV virions from binding to host cells.